Skip to Main Content

And so, another working week will soon draw to a close. This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is rather modest, though. We hope to catch up on chores and reading, and take a few naps. But what about you? You could do some holiday shopping and boost the economy or, perhaps, winterize your castle. Or maybe this is a good time to plan the rest of your life. Well, whatever you do, have a grand time, but be safe. Enjoy and see you soon …

Sanofi is now in advanced talks to acquire Acetlion for about $275 a share, or more than $29 billion, Bloomberg News reports. The price, however, may include a contingent value right, or CVR, for Actelion shareholders, which would pay out depending on the future performance of certain drugs in the Actelion pipeline. A deal would allow Sanofi to bolster its rare disease portfolio while trying to to offset declines for its bestselling Lantus insulin.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!